GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Gross Profit

3D Medicines (HKSE:01244) Gross Profit : HK$640.8 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Gross Profit?

3D Medicines's gross profit for the six months ended in Dec. 2023 was HK$285.0 Mil. 3D Medicines's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was HK$640.8 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. 3D Medicines's gross profit for the six months ended in Dec. 2023 was HK$285.0 Mil. 3D Medicines's Revenue for the six months ended in Dec. 2023 was HK$308.9 Mil. Therefore, 3D Medicines's Gross Margin % for the quarter that ended in Dec. 2023 was 92.28%.

3D Medicines had a gross margin of 92.28% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 4 years, the highest Gross Margin % of 3D Medicines was 92.90%. The lowest was 92.27%. And the median was 92.56%.


3D Medicines Gross Profit Historical Data

The historical data trend for 3D Medicines's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Gross Profit Chart

3D Medicines Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Gross Profit
- 68.55 586.47 640.80

3D Medicines Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial - 224.86 372.26 355.75 285.05

Competitive Comparison of 3D Medicines's Gross Profit

For the Biotechnology subindustry, 3D Medicines's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3D Medicines's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's Gross Profit distribution charts can be found below:

* The bar in red indicates where 3D Medicines's Gross Profit falls into.



3D Medicines Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

3D Medicines's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=694.494 - 53.695
=640.8

3D Medicines's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=308.879 - 23.834
=285.0

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$640.8 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

3D Medicines's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=285.0 / 308.879
=92.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


3D Medicines  (HKSE:01244) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

3D Medicines had a gross margin of 92.28% for the quarter that ended in Dec. 2023 => Durable competitive advantage


3D Medicines Gross Profit Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


3D Medicines (HKSE:01244) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN
3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.
Executives
Gong Zhaolong 2101 Beneficial owner
Zhu Pai 2101 Beneficial owner
Dragon Prosper Holdings Limited 2101 Beneficial owner
Simcere Pharmaceutical Group Limited 2101 Beneficial owner
Gong Zhaolong 2501 Other
Immunal Medixin Us Limited 2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership) 2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd. 2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.) 2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership) 2201 Interest of corporation controlled by you
Zhu Jinqiao 2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines